MIRA INFORM REPORT

 

 

Report Date :           

10.03.2012

 

IDENTIFICATION DETAILS

 

Name :

SCETI KK

 

 

Registered Office :

DF Kasumigaseki Place, 3-6-7 Kasumigaseki Chiyodaku Tokyo 100-0013

 

 

Country :

Japan

 

 

Financials (as on) :

31.12.2011

 

 

Date of Incorporation :

November  2005

 

 

Com. Reg. No.:

0100-01-096581 (Tokyo-Chiyodaku)

 

 

Legal Form :

Limited Company

 

 

Line of Business :

Import, Export, Wholesale of medicine, food ingredients, cosmetic ingredients, etc

 

 

No. of Employees :

60

 

RATING & COMMENTS

 

MIRA’s Rating :

Ba

 

RATING

STATUS

PROPOSED CREDIT LINE

41-55

Ba

Overall operation is considered normal. Capable to meet normal commitments.

Satisfactory

 

Maximum Credit Limit :

Yen 43.8 Million

 

 

Status :

Satisfactory

 

 

Payment Behaviour :

No Complaints

 

 

Litigation :

---

 

 

NOTES:

Any query related to this report can be made on e-mail : infodept@mirainform.com while quoting report number, name and date.

 

ECGC Country Risk Classification List – September 30th, 2011

 

Country Name

Previous Rating

                   (30.06.2011)                  

Current Rating

(30.09.2011)

Japan

a1

a1

 

Risk Category

ECGC Classification

Insignificant

 

A1

Low

 

A2

Moderate

 

B1

High

 

B2

Very High

 

C1

Restricted

 

C2

Off-credit

 

D

 

Company name

 

SCETI KK

 

 

REGD NAME

 

Sceti KK

 

 

MAIN OFFICE

 

DF Kasumigaseki Place, 3-6-7 Kasumigaseki Chiyodaku Tokyo 100-0013 JAPAN

Tel: 03-5510-2651      Fax: 03-5510-0134

                                               

URL:                             http://www.sceti.co.jp

E-Mail address:            medical@sceti.co.jp

 

 

ACTIVITIES

 

Import, export, wholesale of medicine, food ingredients, cosmetic ingredients, etc

 

 

BRANCHES

 

Nil

 

 

OVERSEAS

 

Asia

 

 

OFFICERS

 

FABIEN REYJAL, PRES

Tohru Umezu, dir

Masayoshi Katsuta, dir                                                  

 

Yen Amount:     In million Yen, unless otherwise stated

 

SUMMARY

 

FINANCES        FAIR                             A/SALES          Yen 2,447 M

PAYMENTS      No Complaints          CAPITAL           Yen 150 M

TREND             SLOW                          WORTH            Yen 555 M

STARTED         2005                             EMPLOYES      60

 

 

COMMENT

 

TRADING FIRM SPECIALIZING IN MEDICINES, FOOD INGREDIENTS,  COSMETIC INGREDIENTS, OTHER.

 

FINANCIAL SITUATION CONSIDERED FAIR AND GOOD FOR ORDINARY BUSINESS ENGAGEMENTS.

                       

MAX CREDIT LIMIT: YEN 43.8 MILLION, 30 DAYS NORMAL TERMS

 

 

HIGHLIGHTS

           

The subject company was established originally in 1952 as part of DF Group, as Sceti Co Ltd, and on 01/01/2006 was transferred to Sceti KK, as captioned.  This is a trading firm for import, export and wholesale of nuclear medicines, food ingredients, cosmetics ingredients, other (See OPERATION).

 

 

FINANCIAL INFORMATION

 

Financial are only partially disclosed.

 

The sales volume for Dec/2010 fiscal term amounted to Yen 2,447 million, a 25% down from Yen 3,273 million in the previous term.  The net profit was posted at Yen 151 million, compared with Yen 180 million a year ago.

 

For the current term ending Mar 2012 the net profit is projected at Yen 155 million, on a 2% rise in turnover, to Yen 2,500 million.

 

The financial situation is considered FAIR and good for ORDINARY business engagements.  Max credit limit is estimated at Yen 43.8 million, on 30 days normal terms.

 

 

REGISTRATION

 

Date Registered:  Nov 2005

Regd No.:         0100-01-096581 (Tokyo-Chiyodaku)

Legal Status:      Limited Company (Kabushiki Kaisha)

Authorized:         3,000 shares

Issued:             3,000 shares

Sum:                   Yen 150 million

 

Major shareholders (%): Compagne Commercial Donishiana SA (100)

 

Nothing detrimental is known as to the commercial morality of executives.

 

 

OPERATION

           

Activities: Imports, exports and wholesales nuclear medicine, medical devices, food ingredients, cosmetics ingredients, other (--100%)

 

(Handling Items by Divisions):

 

Medical Science: nuclear medicines, medical devices, research reagents, sterilization solution, other;

 

Life & Food Science: functional food ingredients, food ingredients, nutritional ingredients, bio chemical, other;

 

Beauty Science: cosmetic ingredients, other

 

Clients: [Mfrs, wholesalers] Japan Radioisotope Assn, Nakalai Tesque Inc, L S Products, Terumo Corp, Fukuda Denshi, other

            No. of accounts: 300

            Domestic areas of activities: Nationwide

 

Suppliers: [Mfrs, wholesalers] Iba, Grow Co, Luminous, other

 

Payment record: No Complaints

 

Location: Business area in Tokyo.  Office premises at the caption address are leased and maintained satisfactorily.

 

Bank References:

MUFG (Aoyamadori)

SMBC (Aoyama)

Relations: Satisfactory

 

FINANCES

(In Million Yen)

 

Terms Ending:

　

31/12/2011

31/12/2010

31/12/2009

31/12/2008

Annual Sales

　

2,500

2,447

3,273

2,516

Recur. Profit

　

240

237

　

　

Net Profit

　

155

151

180

57

Total Assets

　

　

N/A

N/A

N/A

Net Worth

　

　

555

404

224

Capital, Paid-Up

　

　

150

150

150

Div.P.Share(¥)

　

　

0.00

0.00

0.00

<Analytical Data>

(%)

(%)

(%)

(%)

    S.Growth Rate

2.17

-25.24

30.09

67.73

    Current Ratio

 

 

..

..

..

    N.Worth Ratio

 

..

..

..

    N.Profit/Sales

6.20

6.17

5.50

2.27

 

Notes: Financials are only partially disclosed.

Forecast (or estimated) figures for the 31/12/2011 fiscal term.

 

 

FOREIGN EXCHANGE RATES

 

Currency
Unit

Indian Rupees

US Dollar

1

Rs.50.02

UK Pound

1

Rs.79.00

Euro

1

Rs.66.18

 

 

RATING EXPLANATIONS

 

RATING

STATUS

 

 

PROPOSED CREDIT LINE

>86

Aaa

Possesses an extremely sound financial base with the strongest capability for timely payment of interest and principal sums

 

Unlimited

71-85

Aa

Possesses adequate working capital. No caution needed for credit transaction. It has above average (strong) capability for payment of interest and principal sums

 

Large

56-70

A

Financial & operational base are regarded healthy. General unfavourable factors will not cause fatal effect. Satisfactory capability for payment of interest and principal sums

 

Fairly Large

41-55

Ba

Overall operation is considered normal. Capable to meet normal commitments.

 

Satisfactory

26-40

B

Capability to overcome financial difficulties seems comparatively below average.

 

Small

11-25

Ca

Adverse factors are apparent. Repayment of interest and principal sums in default or expected to be in default upon maturity

 

Limited with full security

<10

C

Absolute credit risk exists. Caution needed to be exercised

 

 

Credit not recommended

----

NB

New Business

----

 

This score serves as a reference to assess SC’s credit risk and to set the amount of credit to be extended. It is calculated from a composite of weighted scores obtained from each of the major sections of this report. The assessed factors and their relative weights (as indicated through %) are as follows:

 

Financial condition (40%)            Ownership background (20%)                 Payment record (10%)

Credit history (10%)                    Market trend (10%)                                Operational size (10%)

 

 

 

PRIVATE & CONFIDENTIAL : This information is provided to you at your request, you having employed MIPL for such purpose. You will use the information as aid only in determining the propriety of giving credit and generally as an aid to your business and for no other purpose. You will hold the information in strict confidence, and shall not reveal it or make it known to the subject persons, firms or corporations or to any other. MIPL does not warrant the correctness of the information as you hold it free of any liability whatsoever. You will be liable to and indemnify MIPL for any loss, damage or expense, occasioned by your breach or non observance of any one, or more of these conditions

This report is issued at your request without any risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL) or its officials.